Oligodendroglioma Clinical Trial
Official title:
Pilot Trial of NovoTTF -200A (TTFields) in Patients With Newly Diagnosed High Risk Oligodendrogliomas
This pilot clinical trial studies the side effects of NovoTTF-200A device in treating patients with newly diagnosed high risk oligodendroglioma. NovoTTF-200A device is a portable battery operated device which produces tumor treating (TT)Fields in the body by means of surface electrodes placed on the skin. TTFields are very low intensity, intermediate frequency electric fields that may slow the growth of tumor cells in patients with high risk oligodendroglioma.
PRIMARY OBJECTIVES: I. To describe the safety and tolerability of the TTFields treatment in patients with newly diagnosed high risk oligodendroglioma following standard of care treatment. SECONDARY OBJECTIVES: I. To estimate the proportion of patients who tolerated 75% of treatment goal at months 6, 12, 24. II. To estimate the progression free survival time. III. To assess quality of life. IV. To assess whether or not there is a correlation between genomics and the efficacy of the TTFields treatment. OUTLINE: Beginning 4-8 weeks after standard of care treatment, patients wear NovoTTF-200A device over 18 hours daily (QD). Treatment continues for up to 24 months in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 2 months and then monthly thereafter. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02764151 -
First in Patient Study for PF-06840003 in Malignant Gliomas
|
Phase 1 | |
Recruiting |
NCT04843085 -
Proteomic Characterization of Aggressive Oligodendrogliomas
|
||
Completed |
NCT02903784 -
Neural Basis of Language Processing
|
N/A | |
Completed |
NCT00165360 -
Prolonged Daily Temozolomide for Low-Grade Glioma
|
Phase 2 | |
Recruiting |
NCT04541082 -
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
|
Phase 1 | |
Completed |
NCT02530320 -
Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
|
Phase 2 | |
Terminated |
NCT00389090 -
A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
|
Phase 2 | |
Active, not recruiting |
NCT02549833 -
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
|
Phase 1 | |
Recruiting |
NCT06038760 -
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
|
||
Recruiting |
NCT05624736 -
Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
|
||
Recruiting |
NCT05345002 -
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
|
Phase 2 | |
Completed |
NCT03900689 -
Social Determinants of Health in Glioblastoma Population
|
||
Completed |
NCT02747407 -
Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
|
||
Recruiting |
NCT04970615 -
Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models
|
||
Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
Terminated |
NCT01836549 -
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
|
Phase 2 | |
Recruiting |
NCT03796273 -
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
|
Early Phase 1 | |
Terminated |
NCT00031538 -
Genetic Analysis of Brain Tumors
|
||
Completed |
NCT01609790 -
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
|
Phase 2 | |
Not yet recruiting |
NCT05513859 -
Investigational Imaging Technique During Brain Surgery
|
N/A |